ALLMedicine™ Status Asthmaticus Center

Mar 18th, 2023 - Severe, refractory asthma is a life-threatening emergency that may be treated with isoflurane and extracorporeal life support. The objective of this study was to describe the clinical response to isoflurane and outcomes after discharge of children...

Feb 3rd, 2023 - Severe asthma exacerbations in pediatric patients occur frequently and can require pediatric intensive care unit (PICU) admission. To determine if early administration of intravenous magnesium sulfate (IVMg) to pediatric patients experiencing seve...

Dec 5th, 2022 - Approach Considerations Management of acute respiratory failure begins with a determination of the underlying etiology. While supporting the respiratory system and ensuring adequate oxygen delivery to the tissues, initiate an intervention specific...

Dec 5th, 2022 - Approach Considerations Management of acute respiratory failure begins with a determination of the underlying etiology. While supporting the respiratory system and ensuring adequate oxygen delivery to the tissues, initiate an intervention specific...

Dec 5th, 2022 - Approach Considerations Management of acute respiratory failure begins with a determination of the underlying etiology. While supporting the respiratory system and ensuring adequate oxygen delivery to the tissues, initiate an intervention specific...

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

Sep 27th, 2022 - High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering up to 60 L/min of flow. It is a relatively new modality that has been introduced as an alternative to conventional oxygen t...

Sep 19th, 2022 - In the first stage, it is aimed to develop, implement and evaluate a web designed asthma education program for asthma patients. In the second stage, it is to evaluate the effect of the web-designed education program developed for asthmatic patient...

Jul 6th, 2022 - In France, over 2.5 million people suffer from asthma, including one-third of children. This is the chronic respiratory disease leading to the highest rate of hospitalization. The conventional oxygen delivery means in children are the non-rebreath...

Jul 1st, 2022 - This is a prospective study aiming to characterize the pharmacokinetics of methylprednisolone in obese and non-obese children hospitalized for asthma, and to build a metabolomic profile for each cohort. The primary hypothesis is that the obese coh...

Feb 25th, 2022 - This randomized clinical trial will includes 126 patients after taking informed consent who will meet the eligibility criteria. Patients will be randomly distributed in 2 groups on alternate basis as computerized generated number. Improvement will...

Dec 20th, 2021 - The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced Friday. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an add-on maintenanc...

Oct 23rd, 2020 - NEW YORK (Reuters Health) - Venovenous extracorporeal carbon dioxide removal (ECCO2R) may be lifesaving in patients with status asthmaticus refractory to maximal medical therapy, according to a retrospective review. In a paper in Critical Care Med...

Nov 13th, 2019 - A 19-year-old man was diagnosed with relapsing multiple sclerosis (MS) at age 7 and is currently being treated with an infusible monoclonal antibody (mAb) therapy. Early in the day, he receives an infusion at an outpatient clinic.

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.